BioMarin’s Vimizin (elosulfase alfa) Receives NICE Recommendation for the Treatment of Mucopolysaccharidosis Type 4A
Shots:
- NICE has issued final draft guidance recommending elosulfase alfa for routine use in the NHS as a treatment option for the treatment of mucopolysaccharidosis type 4A
- The recommendation was based on the real-world clinical data from 69 patients treated with Vimizim (elosulfase alfa) which showed the long-term benefits with elosulfase alfa treatment indicating deceleration of MPS 4A progression
- Elosulfase alfa has been developed and marketed by BioMarin Pharmaceutical under the trade name Vimizin. Additionally, MPS 4A leads to a reduction in life expectancy in an inherited lysosomal storage disease
Ref: NICE | Image: BioMarin
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
